Retatrutide is an investigational once-weekly injectable triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, targeting appetite, glucose metabolism, and energy expenditure through a single agent
They create and execute pre-clinical research that ultimately guides the development of new pharmacotherapies and clinical approaches. He and his team are contributing to the future of GLP-1s by seeking to understand how the medications can regulate the brains reward center, while also minimizing some of the unpleasant side effects
Best for Recovery or Isolation Stacks Ideal partners include: INTRA for hydration and muscular endurance ZMT to improve testosterone levels and sleep quality during healing phases Due to its potency and receptor affinity, IGF-1 DES is especially useful for regenerative therapy in musculoskeletal injuries. Liou, Growth Hormone & IGF Research Dosage and Cycle Length IGF-1 LR3 and IGF-1 DES require different dosing strategies based on their half-lives, mechanisms of action, and intended use
Journal of the American Geriatrics Society 62(1):16-24
2022 (retatrutide discovery) are the three papers that define the design rationale for each compound
